Analysis Of Clinical Efficacy Of Bacterial Lysate Combined With Vitamin AD In Treatment And Avoidance Of Recurrent Upper Respiratory Tract Infection In Children

objectiveThe effects of single and combined intervention of bacterial lysate and vitamin AD on acute treatment time and immunoglobulin level in children with recurrent upper respiratory tract infections(RURTIs)were analyzed,as well as the effect of preventing recurrent upper respiratory tract infection,this study provides reference for clinical treatment and prevention of RURTIs in children.MethodsA total of 167 children aged 3 to 10 years old who received intravenous drug treatment in Shengyang Children’s Hospital during winter and spring season(winter:December ~ February,spring: March ~ May)from December 2020 to December 2021 were selected.The patients were divided into 4 groups according to the random number table method:vitamin AD treatment group,OM-85 BV treatment group,combined medication group and control group,the specific treatment plan of each group is as follows: vitamin AD treatment group,OM-85 BV treatment group,combined medication group and control group.The specific treatment plans of each group are as follows:(1)Control group: To Xiyanping intravenous infusion,ibuprofen suspension oral and other conventional treatment until the child recoveredt;(2)Vitamin AD treatment group: In addition to the control group,vitamin AD drops(2000 units of vitamin A per capsule,700 units of vitamin D3,1 capsule/time,once a day)were added for 3 months;(3)OM-85 BV treatment group: In the treatment of the control group,the product capsules were added with the bacterial lysate capsule(Trade name:OM-85 BV,3.5mg/ capsule,1 capsule/day,10 days a month,20 days off)for 3 months;(4)combined medication group: In the treatment of the control group,the combination of vitamin AD drops(drug and dose and vitamin AD treatment group)and the OM-85 BV(drug and dose and the OM-85 BV treatment group)for 3 months.The duration of acute clinical symptoms(fever,nasal congestion,runny nose,sore throat),the days of intravenous administration,the level of immunoglobulin 3 months after medication,and the number of recurrent upper and lower respiratory tract infections within 1 year of follow-up were compared between the four groups.Results1.There were no significant differences in gender,age,blood routine,C-reactive protein,creatinase isoenzyme,pre-treatment immunoglobulin(IgG,IgA,IgM),vitamin A and vitamin D levels among the four groups(P>0.05).2.The duration of acute stage clinical symptoms(fever,nasal congestion,runny nose,sore throat)and intravenous administration were different among the four groups(P<0.05).In the duration of clinical symptoms,compared with the control group,the vitamin AD treatment group,the OM-85 BV treatment group and the combined medication group were shortened(P<0.05),the OM-85 BV treatment group and the combined drug group pharynx time shorter(P<0.05),however,the treatment time of the combination group was shorter than that of the other two groups(P<0.05).3.Compared with before medication,the levels of immunoglobulin IgG,IgA and IgM in the vitamin AD treatment group and the combination treatment group after 3months of medication were increased(P<0.05).The levels of IgG and IgA in the treatment group were higher than before(P<0.05,but there was no significant change in IgM level(P>0.05);There was no significant difference in the control group of immunoglobulin IgG,IgA and IgM after 3 months(P>0.05).The drug was compared to the control group after three months,The levels of immunoglobulin IgG,IgA and IgM in vitamin AD treatment group and combined drug treatment group were higher than those in control group(P<0.05),The IgG and IgA levels in the treatment group were higher than those in the control group(P<0.05).After 3 months,the levels of immunoglobulin IgG and IgA in the combination group were higher than those in the vitamin AD and the OM-85 BV treatment groups(P<0.05),IgM is higher than the OM-85 BV treatment group and control group(P<0.05).4.Compared with the control group,the vitamin AD treatment group,the OM-85 BV treatment group and combination treatment group all had fewer upper respiratory tract infections within 1 year of follow-up;the number of upper respiratory infections decreased in the upper levels of the combination treatment group compared with the vitamin AD treatment group and the OM-85 BV treatment group(P<0.05);there was no significant difference between the vitamin AD treatment group and the OM-85 BV treatment group(P<0.05).5.The adverse reactions in the four groups were mild and had no significant impact on treatment,and there was no significant difference in the incidence of adverse reactions between the groups during treatment(P>0.05).ConclusionsThe bacterial lysate combined with vitamin AD in the treatment of RURTIs in children can not only shorten the duration of clinical symptoms and intravenous administration time in the acute phase,but also improve the level of immunoglobulin in children and prevent upper respiratory tract infection,and the clinical efficacy is better than single drug,without serious adverse reactions.